Markus Mandler | Chief Executive Officer and Founder
Tridem Bioscience

Dr. Mandler (CEO and founder of Tridem Bioscience), is a leader in development of active immunotherapies for chronic diseases with > 20 years of collaborative research and management experience. At Tridem he drives the company's R&D-, CMC- and IP strategy and oversees its funding and infrastructure. Prior to Tridem, his career includes a significant role as CSO at ACCANIS (2015-2020) where he was working on mRNA therapeutics in dermal applications. As head of the Neurodegeneration Department at AFFiRiS AG (2004-2015), he was developing new vaccination-based treatments for neurodegenerative diseases, especially focusing on Alzheimer's disease (AD) and synucleinopathies such as Parkinson's disease (PD) and multisystem atrophy (MSA). Dr. Mandler – together with his AFFiRiS team - was responsible for the selection of the first two peptide-based vaccines for PD and MSA ever tested in humans. He has secured numerous national and international grants focusing on advanced vaccine platforms for diseases like AD, PD and psoriasis. These include major Horizon Europe-, Austrian Research Promotion Agency-, Austrian national promotional bank- and Michael J Fox foundation for Parkinson’s Research projects. He has authored >20 publications in high impact journals and is author of over 25 patents and patent applications.